Natalizumab increased clinical remission and clinical response in moderate-to-severe Crohn disease

Irvine, E. Jan
September 2003
ACP Journal Club;Sep/Oct2003, Vol. 139 Issue 2, p44
Academic Journal
Presents a study that compared the effectiveness of natalizumab with that of placebo, in inducing clinical remission and clinical response in patients with moderate-to-severe Crohn disease. Design; Intervention; Outcome measures; Results; Commentary.


Related Articles

  • Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Rutgeerts, Paul; Vermeire, Severine; Van Assche, Gert // Gut;Apr2007, Vol. 56 Issue 4, p453 

    The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that...

  • The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Rutgeerts, P. // Mediators of Inflammation;Jun98, Vol. 7 Issue 3, p137 

    GLUCOCORTICOSTEROIDS are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially...

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Use of azathioprine in IBD: modern aspects of an old drug. Louis, Edouard; Irving, Peter; Beaugerie, Laurent // Gut;Nov2014, Vol. 63 Issue 11, p1695 

    The article focuses on the use of azathioprine in the treatment of inflammatory bowel disease (IBD). Topics discussed include efficacy of azathioprine in treating Crohn's disease (CD), low cost and higher quality and effectiveness of thiopurines in the remission of CD patients, and thioguanine...

  • Understanding the rationale and use of probiotics in the treatment of IBD. Burch, Jennie // Gastrointestinal Nursing;Apr2009, Vol. 7 Issue 3, pS12 

    Probiotics are often in the media, with promises of a reduction in bloating and the provision of 'good' bacteria for all. However, there has also been an interest in their use for specific conditions. Probiotics are non-pathogenic bacteria that confer health benefits beyond their nutritional...

  • MY THOUGHTS ON USING CYCLOSPORINE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE. Korelitz, Burton I. // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2085 

    Deals with the use of cyclosporine in the treatment of inflammatory bowel disease (IBD). Rationale in using cyclosporine in IBD and Crohn's disease; Overview of studies on the use cyclosporine in the treatment of IBD and Crohn's disease; Cases of using cyclosporin in patients with pneumonia;...

  • Therapierefraktäre chronisch entzündliche Darmerkrankungen: Eine chirurgische Herausforderung. Buhr, H.J.; Kroesen, A.J. // Der Chirurg;Nov2013, Vol. 84 Issue 11, p945 

    Surgery for inflammatory bowel disease under immunosuppressant drugs is a widely discussed topic. Because therapeutic concepts have significantly changed, almost no patient is currently without an immunosuppressant or biologic agent prior to surgery. However, the data whether biological agents...

  • Use of biological therapy during pregnancy in the treatment of IBD. Thomas, Rosemarie // Gastrointestinal Nursing;Apr2009, Vol. 7 Issue 3, pS4 

    Ulcerative colitis and Crohn's disease often occur in the younger population, which means they are likely to affect women of child-bearing age. Infliximab and adalimumab, both biological therapies, are being increasingly used to treat moderate-to-severe inflammatory bowel disease (IBD) when...

  • Consumption of Dental Treatment in Patients with Inflammatory Bowel Disease, a Register Study. Johannsen, Annsofi; Fored, Michael C.; Håkansson, Jan; Ekbom, Anders; Gustafsson, Anders // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1 

    Objective: The aim of this study was to compare the consumption of dental treatment among patients with Crohn´s disease (CD) or ulcerative colitis (UC) compared to age and gender matched control groups. Design: The study group comprised 2085 patients with CD and 3161 with UC from the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics